Sarepta Therapeutics (SRPT) Tops Q4 EPS by 29c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
February 26, 2020 4:05 PM ESTCAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the three and twelve months ended December 31, 2019.
The Sarepta team made great progress in service of our vision to be one of the worlds most meaningful leaders in precision genetic medicine in 2019, and profoundly so in the fourth quarter, stated Doug Ingram, Sareptas President and Chief Executive Officer. We continued to serve the Duchenne community with EXONDYS 51, achieving revenue of $100 million in the fourth... More
